Prefusion RSV F proteins and their use

US11878998B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Peter Kwong · Washington, US
• Barney Graham · Rockville, US
• John Mascola · Rockville, US
• Li Ou · Bethesda, US
• Aliaksandr Druz · Germantown, US
• Man Chen · Shanghai, CN
• Wing-Pui Kong · Germantown, US
• Ivelin Georgiev · Nashville, US
• Emily Rundlet · New York, US
• Michael Gordon Joyce · Washington, US
• Yaroslav Tsybovsky · Jefferson, US
• Paul Thomas · Berwyn, US
• Marie Pancera · Seattle, US
• Mallika Sastry · Rockville, US
• Cinque Soto · Rockville, US
• Joseph Van Galen · North Wales, US
• Guillaume Stewart-Jones · Cambridge, US
• Yongping Yang · Potomac, US
• Baoshan Zhang · Bethesda, US
• Ulrich Baxa · Frederick, US

Key dates

• Filing date: Nov 11, 2021
• Grant date: Jan 23, 2024
• Expiry date: Jan 13, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.